Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Bioavailability of tolamolol

J K Faulkner, D A Stopher, R Walden

    European Journal of Clinical Pharmacology
    |February 6, 1976
    PubMed
    Summary
    This summary is machine-generated.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    Non-Anticoagulant Heparin: An In Vitro Investigation of a Novel Therapeutic Approach for Oral Cancer.

    Oral diseases·2025
    Same author

    Maximal stomatal conductance to water and plasticity in stomatal traits differ between native and invasive introduced lineages of Phragmites australis in North America.

    AoB PLANTS·2016
    Same author

    The factor time in fetal heart rate monitoring and the detection of acidosis using the WAS score.

    Zeitschrift fur Geburtshilfe und Neonatologie·2014
    Same author

    Rol genes alter hormonal requirements for protoplast growth and modify the expression of an auxin responsive promoter.

    Plant cell reports·2013
    Same author

    Inefficient expression of the DNA-binding domain of GAL4 in transgenic plants.

    Plant cell reports·2013
    Same author

    Fetal heart rate patterns during delivery complicated by hypoxia and acidosis - a computer-aided analysis.

    Zeitschrift fur Geburtshilfe und Neonatologie·2013

    Capsules offered faster absorption of tolamolol (a beta-blocker) than tablets, but both formulations showed similar effects on exercise heart rate reduction. Tolamolol

    Area of Science:

    • Pharmacokinetics and Pharmacodynamics
    • Cardiovascular Pharmacology
    • Drug Formulation Studies

    Background:

    • Understanding the bioavailability of different drug formulations is crucial for optimizing therapeutic outcomes.
    • Tolamolol is a beta-adrenergic blocking agent used for cardiovascular conditions.
    • Comparing capsule and tablet formulations can reveal differences in drug absorption and efficacy.

    Purpose of the Study:

    • To compare the bioavailability of tolamolol administered via capsule versus tablet formulations.
    • To assess the impact of formulation differences on the pharmacodynamic effects of tolamolol, specifically heart rate reduction during exercise.
    • To investigate the relationship between plasma concentrations and heart rate response over time.

    Main Methods:

    Related Experiment Videos

  • A two-way cross-over study involving eight healthy subjects.
  • Measurement of tolamolol plasma concentrations at various time points up to twelve hours.
  • Assessment of maximum exercise heart rate reduction as a pharmacodynamic marker.
  • Analysis of area under the curve (AUC) for both plasma concentration and heart rate reduction.

    • Main Results:

    • Tolamolol was absorbed more rapidly from capsules compared to tablets.
    • No significant difference was observed in the reduction of maximum exercise heart rate between the two formulations.
    • Area under the curve for plasma concentration and exercise tachycardia reduction did not differ significantly between capsules and tablets.
    • A correlation was found between the logarithm of tolamolol plasma concentration and heart rate reduction between two and twelve hours post-administration.

    Conclusions:

    • While capsule formulation leads to faster tolamolol absorption, it does not result in a significantly different overall effect on exercise heart rate reduction compared to tablets.
    • The pharmacodynamic response (heart rate reduction) is related to plasma concentration over a significant post-absorption period.
    • Both capsule and tablet formulations of tolamolol appear to be therapeutically comparable in terms of their impact on exercise-induced tachycardia.